We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
The use of amisulpride in schizophrenic patients with resistant symptomatology
© Kalfas et al; licensee BioMed Central Ltd. 2009
- Published: 22 April 2010
- Public Health
- Large Dose
- Schizophrenic Patient
- Normal Dose
The purpose of this study was to evaluate the use of the pharmaceutical drug Amisulpride (Solian) in schizophrenic patients with resistant semiology
The material of this study was 21 patients (17 men and 4 women) who were diagnosed with schizophrenic disorder paranoid type based on DSM-IV, and were recorded with durable symptomatology (delusions, paranoid ideas etc.) even though the continuous issuing of Amisulpride in normal doses (800-1200 mg/daily). In these patients was given Amisulpride in larger doses than the proposed (1600-2000 mg/daily). The evaluation was done with the PANSS scale
After a 30 day time interval and while the continuous issuing of Amisulpride in larger doses was observed considerably reprocess of the resistant symptoms, fact that recorded at the grade alleviation at PANSS scale
Is concluding that the continuous issuing of Amisulpride in larger doses than the normal ones help considerably in obliteration of the durable symptoms of schizophrenia.
This article is published under license to BioMed Central Ltd.